Ganqiang Liu, Jiajie Peng, Zhixiang Liao, Joseph J Locascio, Jean-Christophe Corvol, Frank Zhu, Xianjun Dong, Jodi Maple-Grødem, Meghan C Campbell, Alexis Elbaz, Suzanne Lesage, Alexis Brice, Graziella Mangone, John H Growdon, Albert Y Hung, Michael A Schwarzschild, Michael T Hayes, Anne-Marie Wills, Todd M Herrington, Bernard Ravina, Ira Shoulson, Pille Taba, Sulev Kõks, Thomas G Beach, Florence Cormier-Dequaire, Guido Alves, Ole-Bjørn Tysnes, Joel S Perlmutter, Peter Heutink, Sami S Amr, Jacobus J van Hilten, Meike Kasten, Brit Mollenhauer, Claudia Trenkwalder, Christine Klein, Roger A Barker, Caroline H Williams-Gray, Johan Marinus, Clemens R Scherzer
A key driver of patients' well-being and clinical trials for Parkinson's disease (PD) is the course that the disease takes over time (progression and prognosis). To assess how genetic variation influences the progression of PD over time to dementia, a major determinant for quality of life, we performed a longitudinal genome-wide survival study of 11.2 million variants in 3,821 patients with PD over 31,053 visits. We discover RIMS2 as a progression locus and confirm this in a replicate population (hazard ratio (HR) = 4...
June 2021: Nature Genetics